Richardo Boyd
Psychiatric/Mental Health · Kissimmee, FLNPI 1497095798
Payments from drug & device makers
Across 95 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$500
- Alkermes, Inc.$374
- Teva Pharmaceuticals USA, Inc.$217
- Otsuka America Pharmaceutical, Inc.$215
- Edwards Lifesciences$154
- Johnson & Johnson$143
- plus $440 from 12 others
What the payments were for
- Food & beverage$2,044100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $500 |
| Alkermes, Inc. | 16 | $374 |
| Teva Pharmaceuticals USA, Inc. | 10 | $217 |
| Otsuka America Pharmaceutical, Inc. | 9 | $215 |
| Edwards Lifesciences | 4 | $154 |
| Johnson & Johnson | 6 | $143 |
| Lundbeck LLC | 5 | $112 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Neurocrine Biosciences, Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Corium, LLC | 2 | $36 |
| Tris Pharma Inc | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Merck | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,044 in reported general payments places this provider in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 53 | $21,901 |
| VraylarCariprazine Hcl | 13 | $18,669 |
| Aripiprazole | 58 | $8,144 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $2,113 |
| Duloxetine Hcl | 85 | $2,081 |
| Oxcarbazepine | 27 | $1,608 |
| Quetiapine Fumarate | 80 | $1,549 |
| Olanzapine | 48 | $1,215 |
| Vilazodone Hcl | 12 | $1,152 |
| Fluvoxamine Maleate | 12 | $798 |
| Lamotrigine | 84 | $754 |
| Buspirone Hcl | 61 | $738 |
| Prazosin Hcl | 29 | $632 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $571 |
| Haloperidol | 16 | $564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $500 | $18,66913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Kissimmee
- Roger RiveraKissimmee$1.6M
- Trinese HardyKissimmee$30K
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.